Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Website suggested that the unapproved cancer immunotherapy was safe and effective, FDA says.

You may also be interested in...



Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says

FDA issues untitled letter to CBA Research Inc. for touting the safety and efficacy of CBT-1 as a cancer therapy on the company website although the agency has yet to complete review of an NDA for the drug.

IND Promotion Quandary Again Trips Up Burzynski Research Institute

The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.

Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says

The agency sent Validus Pharmaceuticals a letter objecting to web pages that minimize the risk of suicidality with use of the bipolar disorder drug and suggest it does not worsen depression or induce weight gain.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel